Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Metformin
placebo
Glimepiride (HOE490)
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Glimepiride, Metformin, Combination Drug Therapy
Eligibility Criteria
Inclusion Criteria:
- Type 2 Diabetes Mellitus patients treated with constant dose of glimepiride on top of diet and exercise
- Patients who gave informed consent to participate in the study
Exclusion Criteria:
- Patients with HbA1c of < 7.0 % and > 11.0 %
Patients with any following laboratory test abnormality :
- ALT and/or AST: > 3 X ULN
- Neutrophils: < 1,000/mm3 and/or platelets < 100,000/mm3
- Hemoglobin: <11 g/dL
- Creatinine: >= 1.3 mg/dL in case of male or >= 1.0 mg/dL in case of female
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Sanofi-Aventis Administrative Office
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
1
2
Arm Description
Metformin on top of glimepiride Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks
Placebo on top of glimepiride Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks
Outcomes
Primary Outcome Measures
Changes in HbA1c from baseline
Secondary Outcome Measures
Change in the ratio patients with < 7.0% of HbA1c
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00924573
Brief Title
Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride
Official Title
Double-blinded Comparative Study to Investigate the Efficacy and Safety of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride in Patients With T2DM Inadequately Treated With Constant Dose of Glimepiride
Study Type
Interventional
2. Study Status
Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
March 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Primary objective of this study is to confirm the efficacy of HOE490 O (glimepiride/metformin) compared with placebo on top of glimepiride in HbA1c change.
Secondary objectives of this study is to evaluate the safety of HOE490 O (glimepiride/metformin) compared with placebo on top of glimepiride as well as other efficacy parameters
Detailed Description
Patients treated with 2-6mg/day of glimepiride will be recruited. The study period consists of screening phase of 6 weeks and double-blinded phase of 24 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Glimepiride, Metformin, Combination Drug Therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
189 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Metformin on top of glimepiride
Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Placebo on top of glimepiride
Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
Glimepiride (HOE490)
Intervention Description
oral administration
Primary Outcome Measure Information:
Title
Changes in HbA1c from baseline
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Change in the ratio patients with < 7.0% of HbA1c
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 Diabetes Mellitus patients treated with constant dose of glimepiride on top of diet and exercise
Patients who gave informed consent to participate in the study
Exclusion Criteria:
Patients with HbA1c of < 7.0 % and > 11.0 %
Patients with any following laboratory test abnormality :
ALT and/or AST: > 3 X ULN
Neutrophils: < 1,000/mm3 and/or platelets < 100,000/mm3
Hemoglobin: <11 g/dL
Creatinine: >= 1.3 mg/dL in case of male or >= 1.0 mg/dL in case of female
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kaku Kohei, Professor
Organizational Affiliation
Kawasaki Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sanofi-Aventis Administrative Office
City
Tokyo
Country
Japan
12. IPD Sharing Statement
Learn more about this trial
Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride
We'll reach out to this number within 24 hrs